Thursday’s Insider Activity: Major Buys and Sells Hit the Market

Here’s a summary of the most significant insider transactions disclosed on Thursday, October 30, 2025.

TOP BUYS

Booz Allen Hamilton Holding Corp (NYSE:BAH) President and CEO Horacio Rozanski purchased 23,800 shares of Class A Common Stock on October 30, 2025, according to SEC filings. The shares were acquired at a weighted average price of $84.66, with prices ranging from $84.24 to $85.02, representing a total investment of $2,014,908. Following this substantial purchase, Rozanski now directly owns 687,745 shares of the company, including restricted stock units.

Celestica INC (NYSE:CLS) Director Laurette T. Koellner made a significant investment by purchasing 6,000 common shares on October 30, 2025. The acquisition was executed through four separate transactions at prices ranging from $339.68 to $342.44, totaling $2,050,025. This purchase is particularly notable as Celestica trades near its 52-week high of $355.50 and has delivered a remarkable 384% return over the past year. Following the transaction, Koellner now directly owns 6,000 shares of the electronic equipment manufacturer, which currently trades at a P/E ratio of 54.96.

ASA Gold & Precious Metals Ltd (NYSE:ASA) saw ten-percent owner Saba Capital Management, L.P. increase its stake by purchasing 21,975 shares at $45.32 per share on October 28 and 29, 2025. The total transaction amounted to $995,907, with 12,847 shares acquired on October 28 and 9,128 shares on October 29. Following these transactions, Saba Capital now indirectly owns 5,101,815 shares of ASA Gold & Precious Metals.

ELLSWORTH GROWTH & INCOME FUND LTD (NYSE:ECF) ten-percent owner Saba Capital Management, L.P. continued its investment strategy by acquiring 11,604 shares of common stock at $12.28 per share on October 28, 2025. The purchase, valued at $142,497, increased Saba Capital’s total holdings to 1,646,856 shares of the fund.

Cincinnati Financial Corp (NASDAQ:CINF) Director Dirk J. Debbink purchased 1,000 shares of common stock at $153.98 per share on October 28, 2025, for a total investment of $153,980. The transaction, executed through a trust, brought Debbink’s direct ownership to 58,481.748 shares of the insurance company.

TOP SELLS

SCHWAB CHARLES CORP (NYSE:SCHW) Co-Chairman Charles R. Schwab sold 109,150 shares of common stock over two days, generating approximately $10.2 million. On October 28, 2025, Schwab divested 64,400 shares at a weighted average price of $94.0048, totaling $6,053,707, with execution prices ranging from $94.00 to $94.02. The following day, he sold an additional 44,750 shares at a weighted average price of $94.521, bringing in $4,230,016, with prices ranging from $94.19 to $94.77.

Oracle (NASDAQ:ORCL) Director Jeffrey Berg, through The Berg Family Trust, sold 49,361 shares of common stock on October 28, 2025, generating approximately $13.9 million. The sales were executed in four separate transactions with prices ranging from $281.579 to $284.307 per share, involving 9,042 shares, 13,373 shares, 22,724 shares, and 4,226 shares respectively.

Vor Biopharma Inc. (NASDAQ:VOR) saw significant selling from RA Capital Healthcare Fund L.P. and related parties, including Peter Kolchinsky and Rajeev M. Shah, between October 28 and October 30, 2025. The transactions totaled $10,368,938, with prices ranging from $25.12 to $28.18 per share. The sales included 87,828 shares at an average price of $27.10 and 36,483 shares at $28.18 on October 28, followed by 251,518 shares at $25.22 on October 29, and 24,579 shares at $25.12 on October 30. The stock is currently trading at $25, well below its 52-week high of $65.80 but significantly above its low of $2.62.

Travere Therapeutics (NASDAQ:TVTX) Chief Executive Officer Eric M. Dube sold 120,000 shares on October 28 and 29, 2025, generating approximately $3.6 million. The transactions were executed at weighted average prices ranging from $30.1192 to $30.379. These sales come as the stock trades near its 52-week high of $30.97, having gained 72% year-to-date.

United Therapeutics (NASDAQ:UTHR) Executive Vice President & General Counsel Paul A. Mahon sold 11,780 shares on October 30, 2025, generating approximately $4.9 million. The sales were executed at prices ranging from $447.3438 to $454.1471. On the same day, Mahon also exercised stock options to acquire 11,000 shares at $135.42 per share, for a total value of $1,489,619.

Why Insider Transactions Matter

Tracking insider buying and selling activities provides valuable insights for investors seeking to understand corporate confidence levels. Insider purchases often signal that executives believe their company’s stock is undervalued or has strong growth potential, while significant selling may indicate concerns about future performance or simple portfolio diversification. However, investors should remember that insiders trade for various personal reasons, and these transactions should be considered as just one factor within a comprehensive investment strategy, alongside fundamental analysis, industry trends, and broader market conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.